Scientists investigate potential markers for a response to sunitinib in patients with metastatic RCC

(European Association of Urology) Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumours might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma, according to a new study to be presented at the 28th Annual EAU Congress currently on-going in Milan.
Source: EurekAlert! - Social and Behavioral Science - Category: Global & Universal Source Type: news